 |
Research Article
Clinical outcomes of diabetic foot management with Circulat
J. A. Olalde, M. Magarici, F. Amendola, O. del Castillo *, S. Gonzalez, A. Muhammad
Adaptogenic Medical Center, Caracas 1080, Venezuela
email: O. del Castillo (corpgov2004@yahoo.com)
*Correspondence to O. del Castillo, Adaptogenic Medical Center, Calle Luis de Camoens c/c Del Arenal, La Trinidad, Caracas 1080, Venezuela.
Keywords
diabetes • diabetic foot amputation • adaptogens • systemic
Abstract
Major and minor lower-extremity amputation is a common complication among diabetics. Various sources indicate diabetic foot ulcer prevalence at between 2.2% and 15% in diabetics. This study evaluates the efficacy and tolerance of a standardized plant extract combination, Circulat, developed for the prevention and treatment of severe manifestations of type 2 diabetes, such as necrotic damage of the foot. Thus, a retrospective cohort study was carried out in 174 patients treated with Circulat with diabetic foot grades D1-D3, according to The University of Texas Wound Classification System, in 50 medical centers, from 2004 to 2007. Circulat obtained 50.57% complete cure of diabetic foot, significant improvement in 37.9% and prevented amputation in 88.5% of the study's total population. The treatment was well tolerated. Four patients (2.3%) had slight gastrointestinal unrest which did not warrant suspension of treatment. Copyright © 2008 John Wiley & Sons, Ltd.
Received: 15 June 2007; Revised: 8 October 2007; Accepted: 12 November 2007 |
